New Rhein

What New Rhein does

New Rhein Healthcare Investors is a Philadelphia-based private equity and venture capital firm founded in 2011 by Nayan Gregory Parekh, the former head of M&A at Novartis AG. The firm applies a concentrated, hands-on private equity approach to life sciences investing, deploying capital across Funds I, II, and III (over $165 million invested to date across 11 portfolio companies). New Rhein typically holds 30%-90% ownership stakes in 5-7 companies per fund and actively manages portfolio operations through board governance, executive team placement, and clinical/regulatory strategy reshaping. The portfolio spans ophthalmology (Novagali, exited), molecular diagnostics (Biocartis, exited via IPO), neurology (Chase, Neuraptive, Theranica), respiratory (Softhale, exited), oncology, metabolic disease (Alveus Therapeutics), benign prostatic hyperplasia (Butterfly Medical), pulmonary arterial hypertension (Corsair Pharma), and sterile injectable manufacturing (American Injectables).

The firm differentiates through an operational talent network of 50+ Executives in Residence and an advisory board of senior pharmaceutical executives, supplementing its three Managing Partners (Parekh, Ivan Gergel as CMO, and former Cipla Global CEO Subhanu Saxena). New Rhein reports over 100 years of collective experience in sourcing, evaluating, and transacting on novel medical technologies, and reviews more than 300 targeted opportunities annually through its proprietary deal flow channels.

New Rhein's business model is classic private equity fund management: it raises capital from institutional limited partners and family offices, charges management fees on committed capital, and earns carried interest on successful exits. Marquee realizations include the $1B sale of Chase Pharmaceuticals to Allergan (2016), the $110M-plus-milestones sale of Softhale to Sino Biopharma (2021), the $139M sale of Novagali Pharma to Santen (2011), and the 2013 Biocartis IPO. The firm operates from Philadelphia with a European office in Mechelen, Belgium, and affiliated fund entities in Luxembourg and the UK, supporting a transatlantic deal flow platform.

Name

New Rhein

Legal name

New Rhein Healthcare Investors LLC

Website

https://newrhein.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

New Rhein Healthcare Investors is a Philadelphia-based, healthcare-focused private equity and venture capital firm that invests concentrated 30%-90% ownership stakes in 5-7 life sciences companies per fund and actively manages them through a 50+ Executive in Residence network. Founded in 2011, the firm has invested over $165M across three funds and delivered exits to Allergan, Sino Biopharma, Santen, and via IPO.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282), Services-Management Consulting Services (8742)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industries

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD), Industry-Specialist / Sector-Focused M&A Advisory (FSAEAGAJ)

Keywords

• Healthcare venture capital
• Life sciences private equity
• Biotech fund management
• Venture capital investing
• Portfolio company management

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

New Rhein Healthcare Investors is a private venture capital and private equity firm that invests in healthcare and life sciences companies across multiple therapeutic areas and stages of development. The firm operates Funds I, II, and III, deploying capital into concentrated portfolios of 5-7 investments per fund with significant ownership stakes (30%-90%), actively managing portfolio companies through board participation and operational support rather than passive minority investing.

Product overview

New Rhein Healthcare Investors operates as a private equity firm focused on life sciences investments, managing Funds I, II, and III that have invested over $165 million across 11 companies throughout multiple therapeutic areas and stages of development. The firm takes a hands-on private equity approach with concentrated portfolios (5 to 7 investments per fund, with 30% to 90% ownership stakes). The portfolio includes novel medications for treatment of asthma & COPD (Softhale), Benign Prostatic Hyperplasia (Butterfly Medical), migraine (Theranica Nerivio), Pulmonary Arterial Hypertension (Corsair Pharma), Nerve Repair (Neuraptive), and Metabolic disease (Alveus Therapeutics). Notable exits include Softhale (sold to Sino Biopharma for $110M in 2021), Chase Pharmaceuticals (sold to Allergan for $1B in 2016), Novagali Pharma (sold to Santen for $139M in 2011), and Biocartis (exited via IPO in 2013).

Differentiator

Problem solved

Functional benefit

Products and services

• New Rhein Healthcare Investors Fund Management Healthcare-focused venture capital and private equity fund management services offered to limited partners (family offices, institutional investors). The firm manages multiple fund vintages (Funds I, II, III) deploying capital in concentrated 5-7 investment portfolios with 30%-90% ownership stakes in life sciences companies across therapeutic areas including respiratory, ophthalmology, neurology, metabolic disease, and medical devices.
• Portfolio Company Operational Support Services Hands-on operational and strategic support provided to portfolio companies, including executive recruitment, clinical and regulatory strategy guidance, R&D oversight, CMC support, commercialization planning, and M&A execution. Leverages over 50 Executives in Residence (EIRs) with experience from Novo Nordisk, Genentech, Amylin, Otsuka, Ferring Pharma, and Shire, plus an advisory board of senior figures from Bristol-Myers-Squibb, Teva, and Shire.

Quantifiable outcome

• Chase Pharmaceuticals exited for up to $1 billion (2016)
• +4 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered core.

• Alveus Therapeutics InccoreStrategic or Co-development PartnerPortfolio company in Fund III developing next-generation therapeutics for obesity and metabolic diseases. Lead asset ALV-100 is a bifunctional GIPR antagonist/GLP-1R agonist fusion protein in Phase 2 clinical trials.
• American Injectables Inc.coreStrategic or Co-development PartnerPortfolio company in Fund II - a U.S.-based contract development and manufacturing organization (CDMO) for sterile injectables located in Tampa, Florida.
• TheranicacoreStrategic or Co-development PartnerFund III portfolio company developing Nerivio, a non-invasive electrical neuromodulation device for acute migraine treatment. Since New Rhein's 2022 investment, revenues have grown 14x with international distribution partnerships in India, Germany, UK, Spain, and Japan.
• Corsair PharmacoreStrategic or Co-development PartnerFund III portfolio company developing a transdermal prodrug patch for pulmonary arterial hypertension (PAH). Has strategic partnership with United Therapeutics, the market leader in PAH therapies.
• Butterfly MedicalcoreStrategic or Co-development PartnerFund II portfolio company developing an implantable nitinol device for benign prostatic hyperplasia (BPH). CE Mark approved with FDA regulatory filings in progress.
• NeuraptivecoreStrategic or Co-development PartnerFund II portfolio company developing NTX-001 for peripheral nerve repair. Has received FDA Orphan Drug Designation and Breakthrough Therapy Designation.
• SAYVAA PharmacoreStrategic or Co-development PartnerFund II portfolio company developing oral reformulation of existing antiviral treatments.
• Thermo Fisher ScientificcoreChannel Partner/ Reseller/ DistributorNational distribution partner for Biocartis Idylla platform in the U.S. market.
• AmgencoreStrategic or Co-development PartnerAgreement with Biocartis to validate RAS tests for use as companion diagnostic for Vectibix, the first fully human monoclonal anti-EGFR antibody approved by FDA for mCRC.
• Dr. Reddy's LaboratoriescoreChannel Partner/ Reseller/ DistributorStrategic partnership with Theranica for commercializing Nerivio in India and Europe through distribution agreements.
• United TherapeuticscoreStrategic or Co-development PartnerStrategic partnership with Corsair Pharma - market leader in PAH therapies partnering on transdermal treprostinil prodrug patch development.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Atlas Venture: Long-standing life sciences-focused venture firm with a larger AUM and broader biotech portfolio across US and Europe. Atlas is a larger incumbent in healthcare VC with a similar hands-on model but materially greater scale.
• OrbiMed: Largest healthcare-dedicated investment firm globally, spanning venture, growth, and credit across biopharma, medtech, and diagnostics. OrbiMed is a broad incumbent serving as the upper-bound scale benchmark for healthcare-focused firms like New Rhein.

Direct peers

• Omega Funds: Healthcare and life sciences-focused investment firm that co-led Alveus Therapeutics' $159.8M Series A with New Rhein. Omega Funds shares the same healthcare-only mandate and stage-agnostic investment approach.
• Apple Tree Partners: Healthcare-focused life sciences venture and growth equity firm managing $2.9B; New Rhein's CFO Bill Engels previously served as CFO at Apple Tree, and both firms apply concentrated, hands-on operating models to biotech and medtech investments.
• Medicxi: European healthcare-focused venture firm investing across therapeutic assets with a concentrated, science-driven model. New Rhein's VP Russell Keathley was previously on Medicxi's investment team, indicating close strategy and team overlap.
• Andera Partners: Paris-based private equity firm with dedicated life sciences practice; co-led Alveus Therapeutics Series A with New Rhein and co-invested in Chase Pharmaceuticals. Both firms invest concentrated positions in European and US healthcare assets.
• Clarus Ventures: Healthcare-specialist venture capital firm focused on biotech and life sciences; New Rhein CFO Bill Engels held senior financial roles at Clarus, and both firms operate concentrated healthcare portfolios with active board involvement.
• Abingworth: Transatlantic life sciences investment firm with venture and growth strategies across biotech, medtech, and digital health. Abingworth's stage and sector focus and operating-partner model closely parallel New Rhein's approach.
• Forbion: European healthcare-dedicated venture capital firm with multi-stage life sciences strategies; comparable to New Rhein in concentrated European/US biotech bets and operating partner engagement.
• Healthcare Royalty Partners (HCR): Healthcare-focused investment firm pursuing structured transactions and royalties on biopharmaceutical products. New Rhein Principal Akhil Akula previously worked at HCR, reflecting overlap in healthcare investment talent and thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/new-rhein-healthcare-investors-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Rhein